<html><head>
	<title>nby20240620_s8.htm</title>

	<!-- Generated by ThunderDome Portal - 6/21/2024 6:05:03 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 80%;">As filed with the Securities and Exchange Commission on June 21, 2024.</td>
			<td style="width: 20%;">Registration No. 333-</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Washington, D.C. 20549</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM S-8</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">REGISTRATION STATEMENT</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">UNDER</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">THE SECURITIES ACT OF 1933</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NovaBay Pharmaceuticals, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:75.5882352941177%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:34.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware </b></p>
			</td>
			<td style="vertical-align:top;width:34.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>68-0454536</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:34.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p>
			</td>
			<td style="vertical-align:top;width:34.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(I.R.S. Employer Identification No.)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2000 Powell Street, Suite 1150, Emeryville, CA 94608</b><br>
<b>(510) 899-8800</b><br>
(Address, including zip code, of Principal Executive Offices)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2017 Omnibus Incentive Plan</b><br>
(Full title of the plan)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Justin M. Hall, Esq.</b><br>
<b>Chief Executive Officer and General Counsel</b><br>
<b>2000 Powell Street, Suite 1150</b><br>
<b>Emeryville, CA 94608</b><br>
<b>(510) 899-8800</b><br>
(Name, address, and telephone number, including area code, of agent for service)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Copies to:<br>
<b>Abby E. Brown, Esq.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Squire Patton Boggs (US) LLP</b><br>
<b>2550 M Street, Northwest</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, DC 20037</b><br>
<b>(202) 457-6000</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%; padding-left: 36pt;">Large accelerated filer &#9744;</td>
			<td style="width: 50%; padding-left: 18pt;">Accelerated filer &#9744;</td>
		</tr>
		<tr>
			<td style="padding-left: 36pt;">Non-accelerated filer &#9746;</td>
			<td style="padding-left: 18pt;">Smaller reporting company &#9746;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td style="padding-left: 18pt;">Emerging growth company &#9744;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPLANATORY NOTE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Registration Statement on Form S-8 registers a total of 12,219 shares of common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), for issuance under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The shares of Common Stock being registered by this Registration Statement give effect to the Company&#8217;s 1-for-35 reverse stock split that was effective on May 30, 2024 (the &#8220;2024 Reverse Stock Split&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The number of shares of Common Stock available for issuance under the stockholder-approved Plan is subject to an automatic annual increase on the first day of each of the Company&#8217;s fiscal years beginning on January 1, 2018 and ending on January 1, 2027 by an amount equal to (i)&nbsp;four percent (4%)&nbsp;of the number of shares of Common Stock outstanding on the last day of the immediately preceding fiscal year or (ii)&nbsp;such lesser number of shares of Common Stock as determined by the Board of Directors (the &#8220;Board&#8221;). For 2024, the Board authorized an increase of 12,219 shares of the Common Stock under the Plan, consisting of the full four percent (4%) increase allowed pursuant to the Plan&#8217;s evergreen provision. These shares are in addition to the 1,892 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on June 2, 2017 (File No. 333-218469), the 17,582 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on January 19, 2018 (File No. 333-222625) pursuant to the annual increase in 2018 according to the Plan&#8217;s evergreen provision, the 1,470 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on February 7, 2020 (File No. 333-236328) pursuant to the annual increases in 2019 and 2020 according to the Plan&#8217;s evergreen provision (with 558 shares of Common Stock from the 2019 annual increase and 912 shares of Common Stock from the 2020 annual increase), the 1,364 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on January 15, 2021 (File No. 333-252155) pursuant to the annual increase in 2021 according to the Plan&#8217;s evergreen provision, the 1,559 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on May 13, 2022 (File No. 333-264953) pursuant to the annual increase in 2022 according to the Plan&#8217;s evergreen provision, and the 2,326 shares of Common Stock registered on the Company&#8217;s Form S-8 filed on March 31, 2023 (File No. 333-271053) pursuant to the annual increase in 2023 according to the Plan&#8217;s evergreen provision.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since the Plan provides that the annual increase in the aggregate number of shares that may be issued pursuant to the Plan&#8217;s evergreen provision begins for fiscal years commencing January 1, 2018, this Registration Statement accounts for the seventh share increase under the evergreen provision. The number of shares of Common Stock registered under each prior Registration Statement listed above has been adjusted to account for all previous stock splits, including the 2024 Reverse Stock Split (collectively, the &#8220;Reverse Split Transactions&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The contents of the prior Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on June 2, 2017, January 19, 2018, February 7, 2020, January 15, 2021, May 13, 2022 and March 31, 2023 (File Nos. <a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774917010557/nby20170522_s8.htm" style="-sec-extract:exhibit;"><u>333-218469</u></a>, <a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774918000850/nby20180117_s8.htm" style="-sec-extract:exhibit;"><u>333-222625</u></a>, <a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774920002052/nby20200206_s8.htm" style="-sec-extract:exhibit;"><u>333-236328</u></a>, <a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921000770/nby20210114_s8.htm" style="-sec-extract:exhibit;"><u>333-252155</u></a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922012388/nby20220511_s8.htm" style="-sec-extract:exhibit;"><u>333-264953</u></a> and <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774923008873/nby20230328_s8.htm" style="-sec-extract:exhibit;"><u>333-271053</u></a>, respectively), are incorporated herein by reference and made part of this Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Registration Statement relates to securities of the same class as those to which the prior Registration Statements listed directly above relate, and is submitted in accordance with General Instruction E to Form S-8 regarding the Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART</b><b> II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Incorporation of Documents by Reference.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">The following documents filed by the Company with the Commission are incorporated by reference into this Registration Statement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Commission on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1389545/000143774924009417/nby20231231_10k.htm" style="-sec-extract:exhibit;">March 26, 2024</a>, and as amended by Amendment No. 1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Commission on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924009990/nby20231231_10ka.htm" style="-sec-extract:exhibit;">March 29, 2024</a>;</p>
			</td>
		</tr>

</table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Commission on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924015679/nby20240331_10q.htm" style="-sec-extract:exhibit;">May 9, 2024</a>;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company&#8217;s Current Reports on Form 8-K filed with the Commission on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924001062/nby20240108_8k.htm" style="-sec-extract:exhibit;">January 10, 2024</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924007754/nby20240313_8k.htm" style="-sec-extract:exhibit;">March 14, 2024</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924009117/nby20240324_8k.htm" style="-sec-extract:exhibit;">March 25, 2024</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924009336/nby20240325_8k.htm" style="-sec-extract:exhibit;">March 26, 2024</a> (as amended on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924018922/nby20240531_8ka.htm" style="-sec-extract:exhibit;">May 31, 2024</a>), <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774924012586/nby20240419_8k.htm" style="-sec-extract:exhibit;">April 19, 2024</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774924012606/nby20240420_8k.htm" style="-sec-extract:exhibit;">April 22, 2024</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924018612/nby20240529_8k.htm" style="-sec-extract:exhibit;">May 29, 2024</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924018930/nby20240531_8k.htm" style="-sec-extract:exhibit;">May 31, 2024</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924019536/nby20240606_8k.htm" style="-sec-extract:exhibit;">June 7, 2024</a>&nbsp;and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924020277/nby20240614_8k.htm" style="-sec-extract:exhibit;">June 14, 2024</a>; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The description of the Company&#8217;s Common Stock which is contained in the Company&#8217;s registration statement on Form 8-A, as filed with the Commission on <a href="http://www.sec.gov/Archives/edgar/data/1389545/000119312507191730/d8a12b.htm" style="-sec-extract:exhibit;">August 29, 2007</a><u>,</u>&nbsp;as updated by the Company&#8217;s Current Report on Form 8-K filed with the Commission on&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774911004362/novabay_8k-062711.htm" style="-sec-extract:exhibit;">June 29, 2011</a>, and including any amendments or reports filed for the purposes of updating this description, including&nbsp;<a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924009990/nby20231231_10ka.htm" style="-sec-extract:exhibit;">Exhibit 4.1</a>&nbsp;to the Company&#8217;s Annual Report for the year ended December 31, 2023.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any such information so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">Notwithstanding the foregoing, we are not incorporating by reference information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, nor any other document or information deemed to have been furnished and not filed in accordance with Commission rules.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description of Securities. </b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 45pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Interests of Named Experts and Counsel.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">The validity of the issuance of the shares of Common Stock registered under this Registration Statement has been passed upon for the Company by Squire Patton Boggs (US) LLP.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Indemnification of Directors and Officers.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">The Company&#8217;s amended and restated certificate of incorporation, as amended, provides that the liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated to the fullest extent permitted by the Delaware General Corporation Law, as so amended. Under the Delaware General Corporation Law, no director will be personally liable to the Company or the Company&#8217;s stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">for any breach of the duty of loyalty to the Company or the Company&#8217;s stockholders;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">for unlawful payment of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">for any transaction from which the director derived an improper personal benefit.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">The Company&#8217;s amended and restated bylaws provide that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Company is required to indemnify the Company&#8217;s directors and executive officers to the fullest extent not prohibited by Delaware law, subject to limited exceptions;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Company may indemnify the Company&#8217;s other employees and agents as set forth in the Delaware General Corporation Law;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Company is required to advance expenses to the Company&#8217;s directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified, against an undertaking by the indemnified party to repay such advances if it is ultimately determined that the indemnified party is not entitled to indemnification; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the rights conferred in the amended and restated bylaws are not exclusive.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">The information provided above is a summary of relevant provisions of our amended and restated certificate of incorporation, as amended, our amended and restated bylaws and certain provisions of the Delaware General Corporation Law. We urge you to read the full text of these documents, forms of which have been filed with the Commission, as well as the referenced provisions of the Delaware General Corporation Law because they are the legal documents and provisions that will govern matters of indemnification with respect to our directors and officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">The Company has entered into indemnification agreements with each of the Company&#8217;s directors and executive officers that require the Company to indemnify these persons against all direct and indirect costs of any type or nature whatsoever, including attorney&#8217;s fees, witness fees, and other out-of-pocket costs of whatever nature, incurred by the director or officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these people may be made a party by reason of the fact that he or she is or was a director or an executive officer of the Company or is or was serving or at any time serves at the request of the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">The Company has purchased insurance on behalf of any person who is or was a director or officer of the Company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exemption from Registration Claimed.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibits.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description of Document</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918005177/ex_107885.htm" style="-sec-extract:exhibit;"><u>Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company</u><u>&#8217;</u><u>s Annual Report on Form 10-K, as filed with the Commission on March 21, 2018 (File No. 001-33678))</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918011215/ex_115851.htm" style="-sec-extract:exhibit;"><u>Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company</u><u>&#8217;</u><u>s Current Report on Form 8-K, as filed with the Commission on June 4, 2018 (File No. 001-33678))</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774920011939/ex_188182.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on May 28, 2020 (File No. 001-33678))<u>&nbsp;</u></a></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921013167/ex_252546.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on May 24, 2021 (File No. 001-33678))<u>&nbsp;</u></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.5</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922002101/ex_330469.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on February 1, 2022 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.6</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448350.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.7</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924018930/nby20240531_8k.htm" style="-sec-extract:exhibit;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on May 31, 2024 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.8</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921024705/ex_300010.htm" style="-sec-extract:exhibit;">Certificate of Designation for the Series B Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on November 1, 2021 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.9</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448351.htm" style="-sec-extract:exhibit;">Certificate of Designation for the Series C Preferred Stock (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.10</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774923023110/nby20230630_10q.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.7 to the Company&#8217;s Quarterly Report on Form 10-Q, as filed with the Commission on June 30, 2023 (SEC File No. 001-336678)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Reference is made to Exhibits&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918005177/ex_107885.htm" style="-sec-extract:exhibit;">3.1</a>,&nbsp;<a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774918011215/ex_115851.htm" style="-sec-extract:exhibit;">3.2</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774920011939/ex_188182.htm" style="-sec-extract:exhibit;">3.3</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774921013167/ex_252546.htm" style="-sec-extract:exhibit;">3.4</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922002101/ex_330469.htm" style="-sec-extract:exhibit;">3.5</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448350.htm" style="-sec-extract:exhibit;">3.6</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001389545/000143774924018930/nby20240531_8k.htm" style="-sec-extract:exhibit;">3.7</a>, <a href="http://www.sec.gov/Archives/edgar/data/0001389545/000143774921024705/ex_300010.htm" style="-sec-extract:exhibit;">3.8</a>, <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774922027767/ex_448351.htm" style="-sec-extract:exhibit;">3.9</a> and <a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774923023110/nby20230630_10q.htm" style="-sec-extract:exhibit;">3.10</a>.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_691229.htm" style="-sec-extract:exhibit;">Specimen Common Stock Certificate</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.1*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_691230.htm" style="-sec-extract:exhibit;">Opinion of Squire Patton Boggs (US) LLP</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_691435.htm" style="-sec-extract:exhibit;">Consent of WithumSmith+Brown, PC</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.2*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_691230.htm" style="-sec-extract:exhibit;">Consent of Squire Patton Boggs (US) LLP (included in Exhibit 5.1)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">24.1*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774917010557/ex99-1.htm" style="-sec-extract:exhibit;">NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.2</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774917010557/ex99-2.htm" style="-sec-extract:exhibit;">Forms of agreements for use under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:13.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">107*</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:83.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_691232.htm" style="-sec-extract:exhibit;">Filing Fee Table</a></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">*&nbsp; Exhibits marked with an asterisk (*) are filed herewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item&nbsp;9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Undertakings. </b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">Incorporated by reference to Item 9 in the Company&#8217;s Registration Statement on Form S-8, filed with the Commission on June 2, 2017.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" name="poa" title="poa"></a>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California on June 21, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Justin M. Hall</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Justin M. Hall</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Chief Executive Officer and General Counsel</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned officers and directors does hereby constitute and appoint Justin M. Hall or his substitute or substitutes, as his or her true and lawful attorney-in-fact and agent, with full power and authority to do any and all acts and things and to execute and file or cause to be filed any and all instruments, documents or exhibits which said attorney and agent determines may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement and to any and all instruments, documents or exhibits filed as part of, or in conjunction with, this Registration Statement or amendments or supplements thereof, with the powers of substitution and revocation, and each of the undersigned hereby ratifies and confirms all that said attorney and agent, or his substitute or substitutes, shall lawfully do or cause to be done by virtue hereof. In witness whereof, each of the undersigned has executed this Power of Attorney as of the dates indicated below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. This document may be executed by the signatories hereto on any number of counterparts, all of which shall constitute one and the same instrument.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></p>
			</td>
			<td style="vertical-align:top;width:2.8%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align:top;width:9.2%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 31.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 31.1%; border-bottom: 1px solid rgb(0, 0, 0);">/s/&nbsp;Justin M. Hall</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Executive Officer, General Counsel and Director</p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Justin M. Hall</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(principal executive officer)</i></p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">/s/&nbsp;Tommy Law</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interim Chief Financial Officer</p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tommy Law</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(principal financial and accounting officer)</i></p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">/s/&nbsp;Paul E. Freiman</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chairman</p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Paul E. Freiman, Ph.D</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">/s/&nbsp;Julie Garlikov</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Julie Garlikov</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">/s/&nbsp;Swan Sit</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Swan Sit</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">/s/&nbsp;Mijia (Bob) Wu</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mijia (Bob) Wu</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">/s/&nbsp;Yenyou (Jeff) Zheng</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:9.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Yenyou (Jeff) Zheng, Ph.D</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:31.1%;">/s/&nbsp;Yongxiang (Sean) Zheng</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">June 21, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:31.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Yongxiang (Sean) Zheng</p>
			</td>
			<td style="vertical-align:bottom;width:2.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:20.4%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
[{"type": "S-8", "sequence": "1", "filename": "nby20240620_s8.htm", "description": "FORM S-8", "secsgml_size_bytes": 82505}]
{"company-data": {"conformed-name": "NovaBay Pharmaceuticals, Inc.", "cik": "0001389545", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "680454536", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-280388", "film-number": "241060299"}, "business-address": {"street1": "2000 POWELL STREET, SUITE 1150", "city": "EMERYVILLE", "state": "CA", "zip": "94608", "phone": "(510) 899-8800"}, "mail-address": {"street1": "2000 POWELL STREET, SUITE 1150", "city": "EMERYVILLE", "state": "CA", "zip": "94608"}}
nby20240620_s8.htm
As filed with the Securities and Exchange Commission on June 21, 2024.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NovaBay Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
68-0454536
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
2000 Powell Street, Suite 1150, Emeryville, CA 94608
(510) 899-8800
(Address, including zip code, of Principal Executive Offices)
2017 Omnibus Incentive Plan
(Full title of the plan)
Justin M. Hall, Esq.
Chief Executive Officer and General Counsel
2000 Powell Street, Suite 1150
Emeryville, CA 94608
(510) 899-8800
(Name, address, and telephone number, including area code, of agent for service)
Copies to:
Abby E. Brown, Esq.
Squire Patton Boggs (US) LLP
2550 M Street, Northwest
Washington, DC 20037
(202) 457-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers a total of 12,219 shares of common stock, par value $0.01 per share (the "Common Stock"), of NovaBay Pharmaceuticals, Inc., a Delaware corporation (the "Company"), for issuance under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (the "Plan"). The shares of Common Stock being registered by this Registration Statement give effect to the Company's 1-for-35 reverse stock split that was effective on May 30, 2024 (the "2024 Reverse Stock Split").
The number of shares of Common Stock available for issuance under the stockholder-approved Plan is subject to an automatic annual increase on the first day of each of the Company's fiscal years beginning on January 1, 2018 and ending on January 1, 2027 by an amount equal to (i) four percent (4%) of the number of shares of Common Stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of Common Stock as determined by the Board of Directors (the "Board"). For 2024, the Board authorized an increase of 12,219 shares of the Common Stock under the Plan, consisting of the full four percent (4%) increase allowed pursuant to the Plan's evergreen provision. These shares are in addition to the 1,892 shares of Common Stock registered on the Company's Form S-8 filed on June 2, 2017 (File No. 333-218469), the 17,582 shares of Common Stock registered on the Company's Form S-8 filed on January 19, 2018 (File No. 333-222625) pursuant to the annual increase in 2018 according to the Plan's evergreen provision, the 1,470 shares of Common Stock registered on the Company's Form S-8 filed on February 7, 2020 (File No. 333-236328) pursuant to the annual increases in 2019 and 2020 according to the Plan's evergreen provision (with 558 shares of Common Stock from the 2019 annual increase and 912 shares of Common Stock from the 2020 annual increase), the 1,364 shares of Common Stock registered on the Company's Form S-8 filed on January 15, 2021 (File No. 333-252155) pursuant to the annual increase in 2021 according to the Plan's evergreen provision, the 1,559 shares of Common Stock registered on the Company's Form S-8 filed on May 13, 2022 (File No. 333-264953) pursuant to the annual increase in 2022 according to the Plan's evergreen provision, and the 2,326 shares of Common Stock registered on the Company's Form S-8 filed on March 31, 2023 (File No. 333-271053) pursuant to the annual increase in 2023 according to the Plan's evergreen provision.
Since the Plan provides that the annual increase in the aggregate number of shares that may be issued pursuant to the Plan's evergreen provision begins for fiscal years commencing January 1, 2018, this Registration Statement accounts for the seventh share increase under the evergreen provision. The number of shares of Common Stock registered under each prior Registration Statement listed above has been adjusted to account for all previous stock splits, including the 2024 Reverse Stock Split (collectively, the "Reverse Split Transactions").
The contents of the prior Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on June 2, 2017, January 19, 2018, February 7, 2020, January 15, 2021, May 13, 2022 and March 31, 2023 (File Nos.
333-218469
,
333-222625
,
333-236328
,
333-252155
,
333-264953
and
333-271053
, respectively), are incorporated herein by reference and made part of this Registration Statement.
This Registration Statement relates to securities of the same class as those to which the prior Registration Statements listed directly above relate, and is submitted in accordance with General Instruction E to Form S-8 regarding the Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.
PART
II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference.
The following documents filed by the Company with the Commission are incorporated by reference into this Registration Statement:
1.
The Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Commission on
March 26, 2024
, and as amended by Amendment No. 1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Commission on
March 29, 2024
;
2.
The Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the Commission on
May 9, 2024
;
3.
The Company's Current Reports on Form 8-K filed with the Commission on
January 10, 2024
,
March 14, 2024
,
March 25, 2024
,
March 26, 2024
(as amended on
May 31, 2024
),
April 19, 2024
,
April 22, 2024
,
May 29, 2024
,
May 31, 2024
,
June 7, 2024
and
June 14, 2024
; and
4.
The description of the Company's Common Stock which is contained in the Company's registration statement on Form 8-A, as filed with the Commission on
August 29, 2007
,
as updated by the Company's Current Report on Form 8-K filed with the Commission on
June 29, 2011
, and including any amendments or reports filed for the purposes of updating this description, including
Exhibit 4.1
to the Company's Annual Report for the year ended December 31, 2023.
All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any such information so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.
Notwithstanding the foregoing, we are not incorporating by reference information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, nor any other document or information deemed to have been furnished and not filed in accordance with Commission rules.
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
The validity of the issuance of the shares of Common Stock registered under this Registration Statement has been passed upon for the Company by Squire Patton Boggs (US) LLP.
Item 6.
Indemnification of Directors and Officers.
The Company's amended and restated certificate of incorporation, as amended, provides that the liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated to the fullest extent permitted by the Delaware General Corporation Law, as so amended. Under the Delaware General Corporation Law, no director will be personally liable to the Company or the Company's stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:
●
for any breach of the duty of loyalty to the Company or the Company's stockholders;
●
for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
●
for unlawful payment of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law; and
●
for any transaction from which the director derived an improper personal benefit.
The Company's amended and restated bylaws provide that:
●
the Company is required to indemnify the Company's directors and executive officers to the fullest extent not prohibited by Delaware law, subject to limited exceptions;
●
the Company may indemnify the Company's other employees and agents as set forth in the Delaware General Corporation Law;
●
the Company is required to advance expenses to the Company's directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified, against an undertaking by the indemnified party to repay such advances if it is ultimately determined that the indemnified party is not entitled to indemnification; and
●
the rights conferred in the amended and restated bylaws are not exclusive.
The information provided above is a summary of relevant provisions of our amended and restated certificate of incorporation, as amended, our amended and restated bylaws and certain provisions of the Delaware General Corporation Law. We urge you to read the full text of these documents, forms of which have been filed with the Commission, as well as the referenced provisions of the Delaware General Corporation Law because they are the legal documents and provisions that will govern matters of indemnification with respect to our directors and officers.
The Company has entered into indemnification agreements with each of the Company's directors and executive officers that require the Company to indemnify these persons against all direct and indirect costs of any type or nature whatsoever, including attorney's fees, witness fees, and other out-of-pocket costs of whatever nature, incurred by the director or officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these people may be made a party by reason of the fact that he or she is or was a director or an executive officer of the Company or is or was serving or at any time serves at the request of the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.
The Company has purchased insurance on behalf of any person who is or was a director or officer of the Company against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.
Item 7.
Exemption from Registration Claimed.
Not applicable.
Item 8.
Exhibits.
Exhibit No.
Description of Document
3.1
Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company
'
s Annual Report on Form 10-K, as filed with the Commission on March 21, 2018 (File No. 001-33678))
3.2
Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company
'
s Current Report on Form 8-K, as filed with the Commission on June 4, 2018 (File No. 001-33678))
3.3
Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K, as filed with the Commission on May 28, 2020 (File No. 001-33678))
3.4
Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K, as filed with the Commission on May 24, 2021 (File No. 001-33678))
3.5
Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K, as filed with the Commission on February 1, 2022 (File No. 001-33678))
3.6
Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))
3.7
Certificate of Amendment to Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K, as filed with the Commission on May 31, 2024 (File No. 001-33678))
3.8
Certificate of Designation for the Series B Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company's Current Report on Form 8-K, as filed with the Commission on November 1, 2021 (File No. 001-33678))
3.9
Certificate of Designation for the Series C Preferred Stock (incorporated by reference to Exhibit 3.2 of the Company's Current Report on Form 8-K, as filed with the Commission on November 18, 2022 (File No. 001-33678))
3.10
Amended and Restated Bylaws of NovaBay Pharmaceuticals, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.7 to the Company's Quarterly Report on Form 10-Q, as filed with the Commission on June 30, 2023 (SEC File No. 001-336678)
4.1
Reference is made to Exhibits
3.1
,
3.2
,
3.3
,
3.4
,
3.5
,
3.6
,
3.7
,
3.8
,
3.9
and
3.10
.
4.2*
Specimen Common Stock Certificate
5.1*
Opinion of Squire Patton Boggs (US) LLP
23.1*
Consent of WithumSmith+Brown, PC
23.2*
Consent of Squire Patton Boggs (US) LLP (included in Exhibit 5.1)
24.1*
Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)
99.1
NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)
99.2
Forms of agreements for use under the NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.2 to the Company's Registration Statement on Form S-8 (File No. 333-218469), as filed with the Commission on June 2, 2017)
107*
Filing Fee Table
*  Exhibits marked with an asterisk (*) are filed herewith.
Item 9.
Undertakings.
Incorporated by reference to Item 9 in the Company's Registration Statement on Form S-8, filed with the Commission on June 2, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California on June 21, 2024.
NOVABAY PHARMACEUTICALS, INC.
/s/
Justin M. Hall
Justin M. Hall
Chief Executive Officer and General Counsel
KNOW ALL PERSONS BY THESE PRESENTS that each of the undersigned officers and directors does hereby constitute and appoint Justin M. Hall or his substitute or substitutes, as his or her true and lawful attorney-in-fact and agent, with full power and authority to do any and all acts and things and to execute and file or cause to be filed any and all instruments, documents or exhibits which said attorney and agent determines may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement and to any and all instruments, documents or exhibits filed as part of, or in conjunction with, this Registration Statement or amendments or supplements thereof, with the powers of substitution and revocation, and each of the undersigned hereby ratifies and confirms all that said attorney and agent, or his substitute or substitutes, shall lawfully do or cause to be done by virtue hereof. In witness whereof, each of the undersigned has executed this Power of Attorney as of the dates indicated below.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. This document may be executed by the signatories hereto on any number of counterparts, all of which shall constitute one and the same instrument.
Signature
Title
Date
/s/ Justin M. Hall
Chief Executive Officer, General Counsel and Director
June 21, 2024
Justin M. Hall
(principal executive officer)
/s/ Tommy Law
Interim Chief Financial Officer
June 21, 2024
Tommy Law
(principal financial and accounting officer)
/s/ Paul E. Freiman
Chairman
June 21, 2024
Paul E. Freiman, Ph.D
/s/ Julie Garlikov
Director
June 21, 2024
Julie Garlikov
/s/ Swan Sit
Director
June 21, 2024
Swan Sit
/s/ Mijia (Bob) Wu
Director
June 21, 2024
Mijia (Bob) Wu
/s/ Yenyou (Jeff) Zheng
Director
June 21, 2024
Yenyou (Jeff) Zheng, Ph.D
/s/ Yongxiang (Sean) Zheng
Director
June 21, 2024
Yongxiang (Sean) Zheng